نتایج جستجو برای: biologic evolution

تعداد نتایج: 398599  

Journal: :Journal of the American Chemical Society 2012

Journal: :Journal of the Visualization Society of Japan 1994

Journal: :Journal of Nepalese Prosthodontic Society 2020

Journal: : 2021

Léčba dyslipidemie představuje velmi dynamicky rostoucí segment farmakoterapie včetně výroby biologických prostředků. Ty dnes cíleně míří na různé proteiny, které se podílejí syntéze, transportu nebo metabolismu lipoproteinů. Sdělení podává přehled o současných možnostech biologické léčby dyslipidemií a léčivých prostředcích, mají potenciál rozšířit j...

Journal: :Botanical Gazette 1913

Journal: :American journal of surgery 2014
Chad A Purnell Jason M Souza Eugene Park Gregory A Dumanian

BACKGROUND Biologic mesh is commonly used in abdominal wall reconstruction but may result in increased hernia recurrence. There are minimal data on repair of these recurrent hernias. METHODS We conducted a retrospective chart review of 24 patients presenting to a single surgeon with recurrent ventral hernia, previously repaired with biologic mesh. RESULTS Seventeen of 24 study patients unde...

2010
Jérôme Stirnemann Nadia Belmatoug Corine Vincent Olivier Fain Bruno Fantin France Mentré

INTRODUCTION Known biomarkers of Gaucher-disease activity are platelets, chitotriosidase, angiotensin-converting enzyme (ACE), tartrate-resistant acid phosphatase (TRAP) and ferritin. The aim of this study was to retrospectively evaluate the frequency of bone events (BE) and biomarker changes during two periods: diagnosis to first enzyme-replacement therapy (ERT) and the latter to the closing d...

2015
Katsuaki Kanbe Junji Chiba Yasuo Inoue Masashi Taguchi Akiko Yabuki

The aim of this study was to investigate remission and biologic-free remission after orthopaedic surgery and related clinical factors in non-responder to infliximab for rheumatoid arthritis (RA). We analyzed 74 patients who were treated with 3 mg/kg infliximab and methotrexate and underwent orthopaedic surgery after non-responder to infliximab with disease activity score (DAS) 28 (CRP) of ≥3.2....

Journal: :Current Opinion in Rheumatology 2015

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید